Journals / Experimental Biomedical Research / 2022 / Cilt: 5 - Sayı: 1

Riluzole and ranolazine application of prostate cancer: Cancer related testicular and liver tissue damage

Pages
10–22
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: This treatment can be considered a promising protective adjuvant candidate for testes and liver tissue in prostate cancer or cancer therapy-related damage.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this study, utilizing the in vivo Copenhagen rat model possessing prostate cancer, we studied the possible impact of tumorigenesis on testes and liver morphology and whether riluzole (RIL) and ranolazine (RNL) treatment would have any affect or not.
📊
Key Findings & Data:Method: Male Copenhagen rats were divided into four groups: 1) Control group, 2) Cancer group, 3) Cancer + 10 μM Riluzole 4), and Cancer + 2.5 μM / 5 μM Ranolazine group.
💡
Conclusion & Impact:Conclusions: This treatment can be considered a promising protective adjuvant candidate for testes and liver tissue in prostate cancer or cancer therapy-related damage.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: In this study, utilizing the in vivo Copenhagen rat model possessing prostate cancer, we studied the possible impact of tumorigenesis on testes and liver morphology and whether riluzole (RIL) and ranolazine (RNL) treatment would have any affect or not. Method: Male Copenhagen rats were divided into four groups: 1) Control group, 2) Cancer group, 3) Cancer + 10 μM Riluzole 4), and Cancer + 2.5 μM / 5 μM Ranolazine group. The tissue samples of testes and liver were taken and processed for light microscopy, including staining with hematoxylin and eosin. Results: In the cancer group, degenerated seminiferous tubules, cell remnants in the lumen were shown in the testis, and a decrease in the spermatogenic cell line was found. The deterioration in these parameters was milder in the treatment groups and an increase in the number of normal tubules was found. In the cancer group, pyknotic nucleus, mononuclear cell infiltration, hyperemia, vacuolization, disrupted arrangement of hepatocyte plates, sinusoidal dilatations, and degenerated hepatocytes were observed in the liver. However, there was a slight damage in cancer + 10 μM RIL, cancer + 2.5 μM RNL, and cancer + 5 μM RNL groups. Properly hepatocyte arrangement and sinusoidal enlargement were observed. Conclusions: This treatment can be considered a promising protective adjuvant candidate for testes and liver tissue in prostate cancer or cancer therapy-related damage.

🔖

Cite This Article

AYDIN, P. K., BUGAN, İ. (2022). Riluzole and ranolazine application of prostate cancer: Cancer related testicular and liver tissue damage. Experimental Biomedical Research, Cilt: 5 - Sayı: 1, 10–22. https://ajindex.com/articles/512585

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Dolfi SC, Medina DJ, Kareddula A, et al. Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1- specific inhibitor on breast cancer cells. Oncotarget. 2017; 8(27):44639-53
  2. Rizaner N, Uzun S, Fraser SP, et al. Riluzole: Anti-invasive effects on rat prostate cancer cells under normoxic and hypoxic conditions. Basic Clin Pharmacol. 2020;127(4):254-64
  3. Raghubir M, Nowshin Rahman C, Fang J, et al. Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. Oncol Rep. 2020;43(1): 169–76
  4. Hale SL, Shryock JC, Belardinelli L, et al. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol. 2008;44(6):954-67
  5. Antzelevitch C, Nesterenko V, Shryock JC, et al. The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol. 2014; 221:137-68
  6. Nelson M, Yang M, Millican-Slater R, et al. Nav1.5 regulates breast tumor growth and metastatic dissemination in vivo. Oncotarget. 2015;6 (32):32914–29
  7. Bugan I, Kucuk S, Karagoz Z, et al. Antimetastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate. Prostate Cancer Prostatic Dis. 2019; 22 (4):569-79
  8. Ajroud-Driss S, Saeed M, Khan H, et al. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS. Amyotroph Lateral Scler. 2007; 8(5):305- 309
  9. Cheng JW. Ranolazine for the management of coronary artery disease. Clinical Therapeutics. 2006; 28(12):1996-2007
  10. Thu YM, Richmond A. NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev. 2010;21(4):213-26
  11. Valiño-Rivas L, Vaquero JJ, Sucunza D, et al. NIK as a Druggable Mediator of Tissue Injury. Trends Mol Med. 2019; 25 (4):341- 60
  12. Farhood B, Khodamoradi E, Hoseini- Ghahfarokhi M, et al. TGF-β in radiotherapy: mechanisms of tumor resistance and normal tissues injury. Pharmacol Res. 2020; 155:104745
  13. Guth A, Monk E, Agarwal R, et al. Targeting Fat Oxidation in Mouse Prostate Cancer Decreases Tumor Growth and Stimulates Anti-Cancer Immunity. Int J Mol Sci. 2020; 21(24): 9660
  14. Pienta KJ, Abate-Shen C, Agus DB, et al. The current state of preclinical prostate cancer animal models. Prostate. 2008;68 (6):629-39
  15. Tennant TR, Kim H, Sokoloff M, et al. The Dunning model, Prostate. 2000; 43 (4):295- 302
  16. Bugan I, Karagoz Z, Altun S, et al. Gabapentin, an analgesic used agai